• It's Here!

    Etf Pro

    Get the big financial market moves right, bullish or bearish with Hedgeye’s ETF Pro.

  • It's Here


    Identify global risks and opportunities with essential macro intel using Hedgeye’s Market Edges.

Takeaway: We are removing HOLX from Investing Ideas.

***Please be advised that we are removing Hologic from Investing Ideas today.

"Given my bear market view," Hedgeye CEO Keith McCullough writes, "I have everything on a shorter leash. I can always bring things back to the list." Since HOLX was added to our list, the S&P 500 has fallen -8.25%. Shares of Hologic are down 0.58%.

The takeaway right now according to Hedgeye Healthcare Sector Head Tom Tobinis is as follows:

Consensus numbers moved higher and now our 3D updates are slowing. A Breast Health miss coming in F4Q15?

It's looking like the early 2015 strength in facility has faded considerably over the last 3 months.  Even if we assume placements rebound back to a more reasonable level in September, our Breast Imaging and Breast Health revenue estimates feel stretched at $190M and $234M, respectively.  Consensus Breast Health is now $278M.  

HOLX: We Are Removing Hologic From Investing Ideas - z tom 1